Compare FGBI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | CRBP |
|---|---|---|
| Founded | 1934 | 2009 |
| Country | United States | United States |
| Employees | 346 | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 147.4M |
| IPO Year | N/A | 2014 |
| Metric | FGBI | CRBP |
|---|---|---|
| Price | $9.80 | $10.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.60 |
| AVG Volume (30 Days) | 11.8K | ★ 223.3K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $4.31 | $6.10 |
| 52 Week High | $10.55 | $20.56 |
| Indicator | FGBI | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 63.69 | 63.28 |
| Support Level | $7.79 | $7.91 |
| Resistance Level | $10.08 | $11.64 |
| Average True Range (ATR) | 0.35 | 0.71 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 86.57 | 85.59 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.